盘龙药业(002864) - 002864盘龙药业投资者关系管理信息20251113

Group 1: Product Strategy - The company focuses on key products such as the patented "Panlong Seven Tablets," which is part of a diverse portfolio covering 12 functional categories and over 100 product specifications [2] - The product range includes 19 dosage forms and 74 approved drug production numbers, along with health food and health products [2] - Future product development will emphasize functional health foods aimed at increasing bone density and other health benefits [3] Group 2: Marketing Network - The company has established a comprehensive marketing network covering over 5,000 tier-one medical institutions and more than 30,000 retail pharmacies [3] - Collaboration with over 650 commercial partners across 30 provincial administrative regions supports multi-category product sales [3] - The company is leveraging "Internet + Medicine" trends to enhance digital marketing and brand influence [3] Group 3: Traditional Chinese Medicine (TCM) Business - The company has completed the filing of 411 varieties of TCM granules, all approved by the National Medical Products Administration [3] - The company is actively advancing the listing of these products in 18 provinces, including major markets like Beijing and Shandong [3] - A combined model of self-operated teams and agents is being used to develop sales channels, focusing on key regions [3]